RxDoctor Payments Data

Sabena Ramsetty

Infectious Disease · Middletown, NYNPI 1659553394

Payments from drug & device makers

$18,524in general payments, 2019–2025

Across 141 payments — averaging $131.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$16K
  • Gilead$1K
  • Viiv Healthcare Company$453
  • GSK$250
  • Lilly USA, LLC$153
  • Tactile Systems Technology Inc$148
  • plus $384 from 8 others

What the payments were for

  • Speaking & faculty fees$13,87575%
  • Travel & lodging$8475%
  • Food & beverage$3,80221%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,524 in reported general payments places this provider in the 85th percentile of 799 infectious disease providers in New York.

See all infectious disease providers in New York

Medicare billing

Part B allowed, 2024
$165,910
Medicare patients
472
Services billed
1,536

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GenvoyaElviteg/Cob/Emtri/Tenof Alafen64$300,253
DovatoDolutegravir Sodium/Lamivudine55$172,359
BiktarvyBictegrav/Emtricit/Tenofov Ala29$120,138
TivicayDolutegravir Sodium31$91,930
PrezcobixDarunavir/Cobicistat26$73,176
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf11$72,939
DescovyEmtricitabine/Tenofov Alafenam15$44,694
JulucaDolutegravir/Rilpivirine13$42,849
OdefseyEmtricitab/Rilpiviri/Tenof Ala11$42,043
IsentressRaltegravir Potassium15$29,492
Darunavir30$18,858
Fosfomycin Tromethamine60$10,800
Lamivudine25$4,787
ErtapenemErtapenem Sodium13$3,355
Methenamine Hippurate23$2,314

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadGenvoya, Biktarvy, Descovy$1,009$465,086108 claims
Viiv Healthcare CompanyDovato, Tivicay, Juluca$453$307,13899 claims
MerckIsentress$90$29,49215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 799 infectious disease providers in New York.

Other infectious disease in Middletown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →